About Us

Antapodia Therapeutics is a science-driven and emerging biopharmaceutical company providing breakthrough solutions for treating aggressive human cancers. The company leverages 3rd-generation nanocarrier and cutting-edge gene-therapy technologies to develops first-in-class invadopodia-targeted siRNA and antibody therapies. These novel therapeutics have shown dramatic anti-tumor and anti-metastasis efficacy in different types of cancers and are expected to have a high opportunity for clinical success.

Competitive Advantages

  • First-in-class invadopodia-targeted therapeutics suitable for the treatment of advanced and highly metastatic cancers.
  • Novel cancer-specific "Master Invadopodial Regulators (MIRs)" that enable the highly specific targeting of invadopodia on cancer cells.
  • The most advanced 3rd-generation lipid nanoparticle (3gLNP) optimized for siRNA therapeutics.
  • Compelling POM/POC data verifying the preclinical efficacy of lead products.
  • A focused product portfolio suitable for different metastatic cancer types and clinical settings.
  • A solely-owned IP coverage.
  • World-class industrial and academic founders.


  • IND-ready and first-in-human trials in 3 years.
  • Target diseases applicable for orphan drug and fast-track designations.


Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.